Taylor Lyons’ Post

After their divesture, Edwards Lifesciences is on an acquisition spree to double down on the structural heart market by purchasing Genesis Medtech's JC Medical business to boost its transcatheter aortic valve replacement (TAVR) technology. This acquisition includes intellectual property and commercial rights for the innovative J-Valve system, designed to treat severe aortic regurgitation. Alongside this deal, Edwards has invested $25 million in Genesis to fuel further market and product development. This move is part of a broader strategy by Edwards to solidify its grip on the cardiac treatment landscape. Just last month, Edwards shelled out $1.2 billion to acquire JenaValve Technology and Endotronix, both pioneers in heart valve and heart failure technologies. Also on the docket was a $300 million purchase of Innovalve Bio Medical. Why the buying spree amid lower-than-expected TAVR volumes? It appears that Edwards is positioning itself for a strong competitive future, seeing potential in diversified, breakthrough tech to address unmet medical needs. The J-Valve system, which earned a breakthrough device designation from the FDA in August 2023, is another feather in Edwards' cap. Impressively, JC Medical completed enrollment for its early feasibility study in the U.S. in February and has entered the pivotal trial phase. This is a promising stride towards addressing aortic regurgitation and adding significant value to Edwards' already robust portfolio. What are your thoughts on Edwards Lifesciences' latest move? Let's spark a discussion on the evolving landscape of cardiac treatments and acquisitions. #Medtech #Cardiology #M&A

It's no longer a question of if, but when! Johnson & Johnson (J&J) has announced a transformative $13.1 billion deal to acquire Shockwave Medical, bolstering its position in the cardiovascular medical-device market. The acquisition, priced at $335 per share in cash, represents a 4.7% premium over Shockwave's previous closing price. Founded in 2009, Shockwave specializes in innovative devices that treat calcium buildup in arteries, with a remarkable 50% revenue growth last year to $730 million. This strategic move expands J&J's MedTech business into high-growth cardiovascular segments, complementing its previous acquisitions like Abiomed and Laminar. J&J CEO Joaquin Duato highlighted that this acquisition aligns with their strategy to excel in the MedTech sector. Despite potential competition, including from Abbott Laboratories, this acquisition signifies a promising future for J&J and Shockwave's combined expertise. Stay tuned for more updates on this exciting development! Check out the article below! Darin W. White

Johnson & Johnson look to have their sights set on another major acquisition in Shockwave Medical. WSJ cited people familiar with the matter. They said the acquisition talks, if successful, could result in a finalized deal in the coming weeks. Another suitor could also seek a merger with Santa Clara, California–based Shockwave. Founded in 2009, Shockwave Medical has intravascular lithotripsy technology that uses sonic pressure waves to treat people with calcified arterial plaque. 2023 saw them bring in $489.7 million in revenue and their shares are trading 10 times higher than they were when the company initially went public in 2019. This isn’t the first time that Shockwave has been the subject of reports of a potential acquisition. Media reports last year mentioned Johnson & Johnson, Medtronic and Boston Scientific as potential suitors. #vidanews #medtech #medicaldevices #acquisition #cardiovascular

Big Moves in Cardiovascular Tech: Acquisitions Shake Up the Industry The cardiovascular technology landscape is experiencing a wave of consolidation and innovation. Here's a look at some recent acquisitions that are shaping the future of heart health: #Johnson & Johnson made a major splash with its $13.1 billion acquisition of #Shockwave Medical. Shockwave's intravascular lithoplasty (IVL) technology offers a minimally invasive approach to treating coronary artery disease. This deal strengthens J&J's position in a rapidly growing market segment. #AstraZeneca bolstered its cardiovascular portfolio with the $1.8 billion acquisition of #CinCor. This move expands their presence in the treatment of resistant hypertension, a condition where blood pressure remains high despite medication. #Nordson Corporation entered the cardiovascular space by acquiring #Atrion Corporation. Atrion specializes in medical infusion and niche #cardiovascular solutions, broadening Nordson's reach in the medical technology sector. Becton Dickinson (#BD) recently announced a $4.2 billion acquisition of #Edwards #Lifesciences' Critical Care product group. This strategic move bolsters BD's presence in advanced patient monitoring technologies, particularly AI-driven solutions. The combined entity is expected to leverage BD's global reach and Edwards' expertise to create new opportunities in data analysis and #innovation for critical care.

I read the post below from Joe Mullings about the increased M&A activity in med device and how the large strategic players are going to add companies to their portfolios.  I completely agree with his take, many people in our med device community are going to have their professional experience impacted by M&A in 2024.  Here are some thoughts on how to manage yourself and lead teams in this time of uncertainty. I have been part of companies that so desperately wanted to be bought they basically burned the boats in anticipation of a transaction.  I also lead a team that focused on not being bought. “Beat the number every quarter and our valuation will be so high no one will buy us” was one of our mantras.    It worked pretty well from my perspective. Interesting enough, the same exact approach to leadership works in both circumstances.  M&A, and all the rumors that go with it, is an enormous consumer of organizational energy and can be a disastrous distraction to a company. Hyper focus from a leadership team is the best antidote to keep your organization performing. A great litmus test to measure organizational focus is to determine when people start thinking about their own self interest and stop concentrating on the health and success of the business.  If you spend your time thinking about your job security, how much money you might make or what your next promotion might be, you are doing yourself and your team a disservice. I was with an organization that was purchased by a large strategic player and nearly every day the sales force would call each other and spend time speculating, time that should have been spent on what’s important, driving the business forward and spending time with your loved ones.  Self-interest is the killer of organizational productivity. If you are leading a team, managing your own territory or any part of a corporate team, your job is to focus on what you can do today to move the business forward.  It is a natural desire to be in the know, to have access to meetings or information that are interesting and outside the normal doldrums of our everyday responsibilities and to indulge in speculation, both positive and negative. It not sexy or overly appealing to focus on your job or your team instead of thinking about what might happen, but it’s a bedrock of great leadership and a world class team. You may have read some of my posts about “A” Players and how they act and think.  Top performers know how to focus, focus, focus on what is important now.  They control the controllable and don’t spend time worrying about things they cannot influence.  Two final thoughts. Performing well in times of uncertainty will distinguish you and present career opportunities you haven’t imagined.    Finally, people crave security in times of change.  BE A GREAT LEADER.  Exercise high communication, consistency in tone and demeanor, continual encouragement and relentless focus on the objective.  People will notice.

𝗕𝗶𝗹𝗹𝗶𝗼𝗻𝘀 𝗶𝗻 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗗𝗲𝘃𝗶𝗰𝗲𝘀 𝗠&𝗔: 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗺𝗲𝗲𝘁𝘀 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 🥁 In the past 12 months, we've witnessed groundbreaking mergers and acquisitions in the medical devices space, as industry leaders strategically position themselves to drive innovation, expand portfolios, and enhance patient outcomes. Let’s take a look at the biggest deals that have set the stage for a transformative future: 1. Johnson & Johnson made waves with its $𝟭𝟯.𝟭 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 acquisition of Shockwave Medical, strengthening its cardiovascular solutions. 2. BD acquired Edwards Lifesciences’ Critical Care business for $𝟰.𝟮 𝗯𝗶𝗹𝗹𝗶𝗼𝗻, signaling its commitment to advanced care technologies. 3. Boston Scientific took over Axonics, Inc. in a $𝟯.𝟳 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 deal, expanding its portfolio in neuromodulation therapies. 4. Johnson & Johnson is set to acquire V-Wave for $𝟭.𝟳 𝗯𝗶𝗹𝗹𝗶𝗼𝗻, gaining a foothold in the cutting-edge heart failure market. 5. Edwards Lifesciences plans to acquire JenaValve Technology, Inc. and Endotronix for $𝟭.𝟮 𝗯𝗶𝗹𝗹𝗶𝗼𝗻, adding a valuable pipeline of structural heart innovations. 6. Boston Scientific has its eyes on Silk Road Medical, Inc. Medical for $𝟭.𝟭𝟲 𝗯𝗶𝗹𝗹𝗶𝗼𝗻, furthering its commitment to stroke prevention technologies. 7. Boston Scientific also completed the acquisition of #RelievantMedsystems for $𝟴𝟱𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻, enhancing its pain management offerings. 8. Enovis acquired Lima Corporate for $𝟴𝟰𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻, adding to its reconstructive surgery portfolio. 9. Inari Medical wrapped up its $𝟰𝟭𝟱 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 acquisition of LimFlow SA, deepening its focus on endovascular treatments. These strategic moves aren't just numbers—they represent game-changing opportunities to address unmet needs in healthcare, improving patient lives across the globe. 🌍💡 Source: https://lnkd.in/e8B5Rb5Y #MergersAndAcquisitions #MedicalDevices #MedTech #Innovation #JohnsonAndJohnson #BostonScientific #EdwardsLifesciences #BD #Enovis #InariMedical

For those already in the #painspace working for #Abbott, #BostonScientific, #NaluMedical, #Biotronik, #Curonix, #AvanosMedical, #VertosMedical, #Medtronic – what are your thoughts on the trend of smaller mid-tier organizations like Nevro, Vertos, and Nalu being acquired by larger firms in the industry such as Abbott/Boston Scientific? Experienced reps, do you believe these smaller companies bring a stronger vision to rapidly improve patient access to innovative devices? The dynamics between large corporations acquiring smaller firms with advanced technology raises questions about future investments and acquisitions. #medicaldevices #healthcareindustry

🚀Huge news in the cardiac device space 💰Edwards Lifesciences continues its strategic expansion with two major acquisitions totalling $1.2 billion: 🫀 JenaValve Technology, Inc. Technology: Trilogy Heart Valve System for aortic regurgitation (potential FDA approval in late 2025) 📡 Endotronix: Cordella implantable pulmonary artery pressure sensor (FDA-approved) 💡 These acquisitions follow recent deals with Innovalve Bio Medical Ltd. and Affluent Medical, showcasing Edwards Lifesciences' commitment to innovation in structural heart therapies. The acquisitions align with Edwards Lifesciences' strategic shift towards structural heart disease, following the recently announced $4.2 billion sale of its critical care business to BD. #MedTech #StructuralHeart #TMVR #Acquisition

J&J's New Billion-Dollar Star? Johnson & Johnson's Q2 earnings report brings refreshing news! Following the acquisition of Shockwave Medical, J&J's MedTech revenue reached $7.96 billion. While this figure fell slightly short of analysts' expectations, the 4.4% operational growth paints a promising picture. Shockwave's innovative portfolio alone added a 0.4% bump. Chief Financial Officer Joseph Wolk noted that Shockwave added $77 million in sales in just 30 days post-acquisition. He projects it could contribute $500 million by year-end. Similarly, Tim Schmid, J&J MedTech's worldwide chairman, announced that Shockwave could become J&J's 13th business with annual sales over $1 billion. The cardiovascular division overall saw an impressive 18% operational growth, bringing in $1.87 billion in revenue. This, coupled with successful launches in Europe and Japan, highlights J&J's strategic market adaptation. Shockwave could indeed be J&J MedTech's cornerstone in its growth journey. #MedTech #Innovation #J&JGrowth

How does Johnson & Johnson aim to sustain its growth and strategic focus amidst its aggressive acquisitions and changing medtech landscape?   Johnson & Johnson isn't just making waves in the medtech industry; it's orchestrating a symphony of innovation and growth. With Q1 sales surging to a formidable $7.82 billion and cardiovascular sales skyrocketing to $1.81 billion (roughly 20% YoY growth), the numbers speak volumes about J&J's strategic prowess. And let's not forget Abiomed, whose sales jumped to $371 million compared with $324 million in the previous year—a clear indication of momentum.   But what's driving this meteoric rise? One needs only to examine J&J's aggressive acquisition strategy, which has seen the healthcare giant shell out over $30 billion on medtech assets alone in just two years. CEO Joaquin Duato's unwavering commitment to growth underscores the company's long-term vision, with M&A remaining a key priority aimed at driving innovation and enhancing patient care standards.   At the heart of J&J's strategy lies a focused effort on cardiovascular innovation, exemplified by acquisitions like Abiomed and Shockwave Medical. These strategic moves have already paid dividends, with the cardiovascular segment experiencing remarkable growth, particularly in electrophysiology, which saw a staggering 23% year-over-year increase to reach $1.34 billion in sales for the quarter. J&J's pursuit of high-growth markets with groundbreaking technologies sets the stage for even more remarkable feats in the world of medtech.   https://lnkd.in/gX6Di4nv #MedTechNews #MedicalDevices #HealthcareInnovation #MedTechIndustry #HealthTech #HealthcareTechnology #MedDeviceNews #HealthcareNews #MedTechTrends